Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease

Abstract

Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the “expert consensus on the diagnosis and treatment of anticancer DILD” after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.

Keywords

drug-induced interstitial lung disease / anticancer drug / diagnosis / treatment

References

[1] SkeochS, WeatherleyN, SwiftAJ, et al.. Drug-induced interstitial lung disease: a systematic review. J Clin Med, 2018, 7(10): 356

[2] ZhangJ, ShenWN, JiDM, et al.. FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors. China Oncol, 2021, 31(4): 241-249

[3] XuZJ. Enhance the importance and knowledge of drug-induced lung injury. Chin J Tubercul Respir Dis (Chinese), 2017, 40(10): 721-723

[4] SternbachG. William Osler: narcotic-induced pulmonary edema. J Emerg Med, 1983, 1(2): 165-167

[5] RosenowEC. Drug-induced pulmonary disease. Dis Mon, 1994, 40(5): 253-310

[6] LiL, MokH, JhaveriP, et al.. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther, 2018, 18(10): 1041-1057

[7] WuYL, ZhouC, HuCP, et al.. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(2): 213-222

[8] SequistLV, YangJC, YamamotoN, et al.. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27): 3327-3334

[9] ShiYK, WangL, HanBH, et al.. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol, 2017, 28(10): 2443-2450

[10] MaemondoM, InoueA, KobayashiK, et al.. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388

[11] WillemsenAE, GruttersJC, GerritsenWR, et al.. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer, 2016, 138(10): 2312-2321

[12] GongC, XiaoQ, LiY, et al.. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. Oncologist, 2021, 26(4): e580-e587

[13] ChuziS, TavoraF, CruzM, et al.. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res, 2017, 9: 207-213

[14] KhojaL, DayD, Wei-Wu ChenT, et al.. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol, 2017, 28(10): 2377-2385

[15] ChanKK, BassAR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, 2020, 369: m736

[16] KhungerM, RakshitS, PasupuletiV, et al.. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest, 2017, 152(2): 271-281

[17] PillaiRN, BeheraM, OwonikokoTK, et al.. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer, 2018, 124(2): 271-277

[18] CortésJ, KimSB, ChungWP, et al.. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med, 2022, 386(12): 1143-1154

[19] CortésJ, KimSB, ChungWP, et al.. Trastuzumab deruxtecan (T-DXd) vs. trastuzumab emtansine (TDM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast 03 study. Ann Oncol, 2021, 32(suppl_5): S1283-S1346

[20] MatsunoO. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res, 2012, 13(1): 39

[21] DelaunoisLM. Mechanisms in pulmonary toxicology. Clin Chest Med, 2004, 25(1): 1-14

[22] OhtaH, ChibaS, EbinaM, et al.. Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol, 2012, 302(2): L193-L205

[23] RyrfeldtA. Drug-induced inflammatory responses to the lung. Toxicol Lett, 2000, 112–113: 171-176

[24] ChatmanLA, MortonD, JohnsonTO, et al.. A strategy for risk management of drug-induced phospholipidosis. Toxicol Pathol, 2009, 37(7): 997-1005

[25] SadowskaAM, SpecenierP, GermonpreP, et al.. Antineoplastic therapy-induced pulmonary toxicity. Expert Rev Anticancer Ther, 2013, 13(8): 997-1006

[26] KaliszKR, RamaiyaNH, LaukampKR, et al.. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. Radiographics, 2019, 39(7): 1923-1937

[27] JohkohT, LeeKS, NishinoM, et al.. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest, 2021, 159(3): 1107-1125

[28] RaghuG, Remy-JardinM, MyersJL, et al.. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68

[29] DesaiSR, ProschH, GalvinJRHodlerJ, Kubik-HuchRA, von SchulthessGK. Plain Film and HRCT Diagnosis of Interstitial Lung Disease. Diseases of the Chest, Breast, Heart and Vessels 2019-2022: Diagnostic and Interventional Imaging, 2019, Cham (CH), Springer: 37-45

[30] AkiraM, SuganumaN. Acute and subacute chemicalinduced lung injuries: HRCT findings. Eur J Radiol, 2014, 83(8): 1461-1469

[31] BatraK, ButtY, GokaslanT, et al.. Pathology and radiology correlation of idiopathic interstitial pneumonias. Hum Pathol, 2018, 72: 1-17

[32] Zare MehrjardiM, KahkoueeS, PourabdollahM. Radiopathological correlation of organizing pneumonia (OP): a pictorial review. Br J Radiol, 2017, 90(1071): 20160723

[33] CostabelU, MiyazakiY, PardoA, et al.. Hypersensitivity pneumonitis. Nat Rev Dis Primers, 2020, 6(1): 65

[34] KligermanSJ, FranksTJ, GalvinJR. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics, 2013, 33(7): 1951-1975

[35] ObadinaET, TorrealbaJM, KanneJP. Acute pulmonary injury: high-resolution CT and histopathological spectrum. Br J Radiol, 2013, 86(1027): 20120614

[36] SalvatoreM, SmithML. Cross sectional imaging of pulmonary fibrosis translating pathology into radiology. Clin Imaging, 2018, 51: 332-336

[37] DelaunayM, CadranelJ, LusqueA, et al.. Immunecheckpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): 1700050

[38] RaghuG, CollardHR, EganJJ, et al.. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011, 183(6): 788-824

[39] American Thoracic Society/European Respiratory Society^.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias^.. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med, 2002, 165(2): 277-304

[40] MattilaJT, FineMJ, LimperAH, et al.. Pneumonia. Treatment and diagnosis. Ann Am Thorac Soc, 2014, 11(Suppl4): S189-S192

[41] LatimerKM, MottTF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician, 2015, 91(4): 250-256

[42] AncionA, LopezR, D’OrioV, et al.. Embolie pulmonaire aiguë: paradoxes, jugements et évidences. Rev Med Liege, 2018, 73(5–6): 319-325

[43] KomiyaK, AkabaT, KozakiY, et al.. A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. Crit Care, 2017, 21(1): 228

[44] TsuchiyaN, GriffinL, YabuuchiH, et al.. Imaging findings of pulmonary edema: Part 1. Cardiogenic pulmonary edema and acute respiratory distress syndrome. Acta Radiol, 2020, 61(2): 184-194

[45] LindPA, MarksLB, HardenberghPH, et al.. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys, 2002, 52(1): 137-143

[46] SchwaiblmairM, BehrW, HaeckelT, et al.. Drug induced interstitial lung disease. Open Respir Med J, 2012, 6: 63-74

[47] MooreMJ, GoldsteinD, HammJ, et al.. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25(15): 1960-1966

[48] NaidooJ, WangX, WooKM, et al.. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol, 2017, 35(7): 709-717

[49] ShannonVR, AndersonR, BlidnerA, et al.. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer, 2020, 28(12): 6145-6157

[50] PramanaA, BrowneL, CoxH, et al.. Pulmonary fibrosis following breast adjuvant radiation therapy: the modifying effects of endocrine and chemotherapy (PULp FICTion). Int J Radiat Oncol Biol Phys, 2015, 93(3): S106

[51] Gemzar® (Gemcitabine) [Prescribing Information]. Lilly USA, 2021. [Available from: https://www.lillymedical.com/en-us/medical-information/oncology/gemzar]

[52] BrahmerJR, LacchettiC, SchneiderBJ, et al.. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018, 36(17): 1714-1768

[53] National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] V5.0. [Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50]

[54] Chinese Anti-Cancer Association, Committee of Lung Cancer Society.. EGFR-TKI ADR Management Chinese Expert Consensus. Chin J Lung Cancer (Chinese), 2019, 22(2): 57-81

[55] Chinese Society of Clinical Oncology (CSCO) management guideline of toxicities from immune checkpoint inhibitors (Chinese). 2021. [Available from: http://meeting.csco.org.cn/MUser/M/1?returnurl=http://www.csco.org.cn/cn/index.aspx]

[56] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in Oncology. Management of Immunotherapy-Related Toxicities. 2022. [Available from: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf]

[57] ENHERTU (fam-trastuzumab deruxtecan-nxki) [Prescri-bing Information]. Daiichi-Sankyo 2019. [Available from: https://daiichisankyo.us/prescribinginformation-portlet/getPIContent?productName=Enhertu&inline=true]

[58] KuboK, AzumaA, KanazawaM, et al.. Consensus statement for the diagnosis and treatment of druginduced lung injuries. Respir Investig, 2013, 51(4): 260-277

[59] PuzanovI, DiabA, AbdallahK, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017, 5(1): 95

[60] TrinhS, LeA, GowaniS, et al.. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs, 2019, 6(2): 154-160

[61] RicheldiL, duB R, RaghuG, et al.. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2071-2082

[62] KingTEJr, BradfordWZ, Castro-BernardiniS, et al.. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-2092

[63] DempseyTM, SangaralinghamLR, YaoX, et al.. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 2019, 200(2): 168-174

[64] TianGZ, WangJ, GaoZCDrug-induced lung injury, 2015, Beijing, People’s Medical Publishing House

[65] YangZG. Progress of the Treatment of Interstitial Lung Diseases by Chinese Medicine. Shanghai J Tradit Chin Med (Chinese), 2003, 37(4): 60-64

[66] SpruitMA, SinghSJ, GarveyC, et al.. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med, 2013, 88(8): e13-e64